"# Keynan S, Hooper NM, Felici A, Amicosante G, Turner AJ: The renal membrane dipeptidase (dehydropeptidase I) inhibitor, cilastatin, inhibits the bacterial metallo-beta-lactamase enzyme CphA. Antimicrob Agents Chemother. 1995 Jul;39(7):1629-31. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/7492120"@en . "Cilastatin"@en . "(Z)-7-((R)-2-Amino-2-carboxy-ethylsulfanyl)-2-[((S)-2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acid"@en . . "(Z)-(S)-6-Carboxy-6-[(S)-2,2-dimethylcyclopropanecarboxamido]hex-5-enyl-L-cysteine"@en . . . . "Cilastatinum"@en . . . . . . . . . . . . . . . "A renal dehydropeptidase-I and leukotriene D4 dipeptidase inhibitor. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to increase its effectiveness. The drug also inhibits the metabolism of leukotriene D4 to leukotriene E4. [PubChem]"@en . "approved"@en . . . . . . . . . . . "82009-34-5"@en . . "Cilastatina"@en . . . . . . "Cilastatin is a specific and reversible renal dehydropeptidase-I inhibitor. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to block the metabolism and thus the inactivation of imipenem so that antibacterial levels of imipenem can be attained in the urine. The drug also prevents the metabolism of leukotriene D4 to leukotriene E4 through the inhibition of leukotriene D4 dipeptidase."@en . . . "Cilastatine"@en . "Humans and other mammals"@en . . "Combined intravenously with imipenem in order to protect it from dehydropeptidase and prolong its antibacterial effect."@en . . . . . "(L)-7-(2-Amino-2-carboxy-ethylsulfanyl)-2-[(2,2-dimethyl-cyclopropanecarbonyl)-amino]-hept-2-enoic acid"@en . "Yatendra Kumar, \"Process for the preparation of amorphous cilastatin sodium.\" U.S. Patent US20040152780, issued August 05, 2004."@en . .